Drug intelligence / Profile preview

E19

Development stage: Preclinical
Modality: Peptides

Overview

E19 is a 39-amino acid analogue of Exendin-4, designed as a potent glucagon-like peptide-1 receptor agonist. It was developed to address the poor solubility and aggregation propensity of Exendin-4, which can lead to unwanted side effects. E19 maintains the tertiary structure of Exendin-4 but exhibits improved helicity, reduced tendency for oligomerization, and preserved biological activity. This makes E19 a promising lead compound for further drug discovery, particularly for the treatment of type 2 diabetes.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on E19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E19.

Explore the full profile